OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

NEXT STORY
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
PREV STORY
Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News

Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021

author_avatar
NASDAQ Market News

pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis

WATERTOWN, Mass. and NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) ...

author_avatar
NASDAQ Market News